My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuraxis, Inc. Common Stock (NY:NRXS)

3.140 -0.190 (-5.71%)
Official Closing Price Updated: 8:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 188,944
Open 3.360
Bid (Size) 2.900 (10)
Ask (Size) 3.440 (8)
Prev. Close 3.330
Today's Range 3.060 - 3.440
52wk Range 1.330 - 6.200
Shares Outstanding 9,858,716
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Earnings Outlook For Neuraxis
 
Via Benzinga

Performance

YTD
+33.6%
+33.6%
1 Month
+29.2%
+29.2%
3 Month
+15.4%
+15.4%
6 Month
+96.2%
+96.2%
1 Year
+4.7%
+4.7%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top movers in Tuesday's after hours session
Via Chartmill
Earnings Scheduled For May 12, 2025
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024
Via InvestorPlace
NRXS Stock Earnings: Neuraxis Reported Results for Q1 2024
Via InvestorPlace
Earnings Scheduled For August 12, 2025
Via Benzinga
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings
Via Benzinga
Nasdaq Falls 100 Points; Home Depot Sales Top Views
Via Benzinga
Earnings Scheduled For March 20, 2025
Via Benzinga
NRXS Stock Earnings: Neuraxis Misses Revenue for Q4 2023
Via InvestorPlace
Earnings Scheduled For April 9, 2024
Via Benzinga
With Only 1.21 Million In The Trading Float, NeurAxis Stock Volatility Exposes An Opportunity, Not A Deterrent ($NRXS)
Via AB Newswire
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
Via Benzinga
CEO Spotlight: NeurAxis CEO Explains His Better Way Of Treating Pediatric IBS And FAP ($NRXS)
Via AB Newswire
SoftBank-Owned Arm, Instacart File To Go Public
Via Talk Markets
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
NeurAxis Looks To Revolutionize The Treatment Of Adolescent Stomach Issues
Via Benzinga
EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids
Via Benzinga
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
From NeurAxis, Inc.
Via GlobeNewswire
Alcoholic Beverage Marketing Company LQR Debuts On Nasdaq
Via Talk Markets
Topics Initial Public Offering
Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.
Via ACCESSWIRE
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
From NeurAxis, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Neuraxis, Inc. Common Stock publicly traded?
Yes, Neuraxis, Inc. Common Stock is publicly traded.
What exchange does Neuraxis, Inc. Common Stock trade on?
Neuraxis, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Neuraxis, Inc. Common Stock?
The ticker symbol for Neuraxis, Inc. Common Stock is NRXS on the New York Stock Exchange
What is the current price of Neuraxis, Inc. Common Stock?
The current price of Neuraxis, Inc. Common Stock is 3.140
When was Neuraxis, Inc. Common Stock last traded?
The last trade of Neuraxis, Inc. Common Stock was at 10/16/25 08:00 PM ET
What is the market capitalization of Neuraxis, Inc. Common Stock?
The market capitalization of Neuraxis, Inc. Common Stock is 30.96M
How many shares of Neuraxis, Inc. Common Stock are outstanding?
Neuraxis, Inc. Common Stock has 31M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.